| Identification | Back Directory | [Name]
Endoxifen | [CAS]
112093-28-4 | [Synonyms]
Avacopan
Endoxifen
Endoxifen(Z)
(Z)-Endoxifen
Endoxifen (Z-isomer)
salt CAS1032008-74-4
Endoxifen HCl Endoxifen Z-isomer
(Z)-4-Hydroxy-N-desmethyl Tamoxifen
Endoxifen Z-isomer (contains 3% E isomer))
(Z)-4-Hydroxy-N-DesMethyl TaMoxifen (Endoxifen)
(Z)-4-Hydroxy-N-desmethyl Tamoxifen (mixture of isomers)
(Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains 3% E isomer)
(Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer)
Tamoxifen Citrate Impurity 17((Z)-4-Hydroxy-N-Desmethyl Tamoxifen)
4-[(Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
(Z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
4-[(1Z)-1-{4-[2-(methylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol
4-[(1Z)-1-[4-[2-(Methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]phenol
Phenol, 4-[(1Z)-1-[4-[2-(MethylaMino)ethoxy]phenyl]-2-phenyl-1-butenyl]-
(E/Z)-4-[1-[4-[2-(Methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-phenol
Phenol, 4-[(1Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-
(Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer)
see D292043 | [Molecular Formula]
C25H27NO2 | [MOL File]
112093-28-4.mol | [Molecular Weight]
373.49 |
| Chemical Properties | Back Directory | [Melting point ]
127-129°C | [Boiling point ]
519.3±50.0 °C(Predicted) | [density ]
1.099±0.06 g/cm3(Predicted) | [storage temp. ]
Amber Vial, -86°C Freezer, Under Inert Atmosphere | [solubility ]
DMSO : 50 mg/mL (133.87 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | [form ]
Powder | [pka]
10.36±0.15(Predicted) | [color ]
White to off-white | [Stability:]
Light Sensitive, Temperature Sensitive |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White to Pink Solid | [Uses]
A novel active metabolite of the anti-cancer drug Tamoxifen (T006000). It showed potent ER binding property, blocked estrogen stimulated growth of breast cancer cell and half maximal inhibition of estrogen responsive gene expression in ER pos. human breast cancer cell line. | [Uses]
A novel active metabolite of the anti-cancer drug Tamoxifen. It showed potent ER binding property, blocked estrogen stimulated growth of breast cancer cell and half maximal inhibition of estrogen responsive gene expression in ER pos. human breast ca | [Definition]
ChEBI: 4-Hydroxy-N-desmethyltamoxifen is a stilbenoid. | [Biological Activity]
(Z)-Endoxifen (endoxifen) is an active tamoxifen metabolite generated via actions of cytochrome P450 (CYP) enzymes CYP3A4/5 and CYP2D6. Endoxifen is more potent than tamoxifen as a selective estrogen receptor modulator (SERM) both in vitro and in vivo with good pharmacokinetics and oral availability (∼80% MCF-7 tumor growth inhibition with 4-8 mg/kg/day endoxifen or 20 mg/kg/day tamoxifen in mice via p.o.). Endoxifen also exhibits 4-fold higher PKC inhibitory potency than tamoxifen and can overcome tamoxifen resistance due to cytochrome CYP2D6 polymorphism. | [in vivo]
Z-Endoxifen (Z-isomer) (5 mg/kg/day, s.c., gradual drug release every 30 days, pellets replaced every 90 days) effectively prevents breast cancer in the C3(1)-TAg mouse model[3].
Z-Endoxifen (50 mg/kg, p.o., 5 times a week for 4 weeks) shows better antitumor efficacy in the MCF7LR resistant mouse model[4].
Z-Endoxifen (75 mg/kg, p.o., once daily for 4 weeks) shows strong antitumor activity in the MCF7AC1 mouse breast cancer model[4]. | Animal Model: | C3(1)-TAg mouse mammary tumorigenesis model, developed by breeding FVB/NJ females with FVB/C3(1)-TAg males (8 weeks), resulting in SV40 T-antigen expression in mammary gland cells and tamoxifen resistance[3] | | Dosage: | 5 mg/kg/day | | Administration: | Subcutaneously implanted pellets, replaced every 90 days, with each pellet designed to release the drug gradually over 30 days. | | Result: | Significantly increased tumor latency and reduced tumor growth. |
| Animal Model: | MCF7LR mouse breast cancer model, simulating endocrine-resistant breast cancer, developed by prolonged exposure to Letrozole[4] | | Dosage: | Z-Endoxifen: 50 mg/kg (Tamoxifen (HY-13757A): 500 μg/day, Exemestane (HY-13632): 250 μg/day，Everolimus (HY-10218): 2.5 mg/day) | | Administration: | Z-Endoxifen: oral gavage (p.o.), the others administered subcutaneously, 5 times a week for 4 weeks | | Result: | Significantly reduced tumor volume in the MCF7LR resistant model compared to Tamoxifen and Exemestane. |
| [storage]
Store at -20°C |
|
|